Iomai Study Shows Self-Applied Travelers' Diarrhea Vaccine Patch Comparable to Clinician-Applied Vac... (es that are viable only through transcut...)

Iomai Study Shows Self-Applied Travelers' Diarrhea Vaccine Patch Comparable to Clinician-Applied Vaccine Patch

Date:2/12/2008

es that are viable only through transcutaneous administration and expand the global vaccine market. Iomai currently has four product candidates in development: three targeting influenza and pandemic flu and one to prevent travelers' diarrhea. For more information on Iomai, please visit http://www.iomai.com.

Some matters discussed in this press release constitute "forward-looking statements" that involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. Such forward-looking statements include statements that Iomai will successfully commercialize its travelers' diarrhea vaccine patch; that such vaccine would be approved with self-application of any dose; statements about Iomai's plans to initiate a Phase 3 study in the summer of 2009 and the potential size of the market for a travelers' diarrhea vaccine; and that, if approved, Iomai's vaccine would be the first available in the U.S. Applicable risks and uncertainties include, among others, that Iomai may not be able to enroll sufficient numbers of patients in future clinical trials; that future clinical trials may not replicate results seen in the trial described in this press release; that Iomai may be unable to obtain the regulatory approvals or financing necessary to conduct additional clinical trials, to conduct those trials in the indicated timeframes or to market any product for travelers' diarrhea; that the FDA or other regulatory authorities may not concur with Iomai's analysis of the trial results described in this press release; that estimates of market size overstate the number of travelers who would use such a product, if it were approved; that competitors may develop products that are safer, more effective, or more convenient to use; and the risks identified under the heading "Factors That May Impact Future Results" in Management's Discussi
'/>"/>

SOURCE Iomai Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine news :

1. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. Study, meta-analysis examine factors associated with death from heatstroke
5. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
6. Study says COPD testing is not measuring up
7. Preclinical study suggests organ-transplant drug may aid in lupus fight
8. Ability to cope with stress can increase good cholesterol in older white men, study finds
9. High alcohol consumption increases stroke risk, Tulane study says
10. Mailman School of Public Health study examines link between racial discrimination and substance use
11. Pitt study finds inequality in tobacco advertising

Post Your Comments:

Iomai Study Shows Self-Applied Travelers' Diarrhea Vaccine Patch Comparable to Clinician-Applied Vac...(es that are viable only through transcut...),Health